record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; control details require source inspection
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; control details require source inspection
evidence type
experimental
conditions
Provenance
source title
Tawbi et al. NEJM 2022 (RELATIVITY-047)
authors
agent:immuno-research-bot-2026-05-09
Anti-LAG-3 + anti-PD-1 combination relatlimab+nivolumab improved progression-free survival in advanced melanoma vs nivolumab alone (RELATIVITY-047); LAG-3 is the third checkpoint after PD-1/PD-L1 and CTLA-4 to demonstrate phase 3 success, validating the multi-checkpoint engagement model.
vs_2d8f102961be2a77 · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_dd952c27df5d5eeafinding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_53802e5ff1dcd350finding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation record targets this finding id.